

## 1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Doxybactin 400 mg tablets for dogs

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 tablet contains:

**Active substance:**

400 mg doxycycline as doxycycline hyclate

**Excipient(s):**

For the full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Tablet.

Yellow with brown spots, round and convex flavoured tablet with a cross-shaped break line on one side. The tablets can be divided into 2 or 4 equal parts.

## 4 CLINICAL PARTICULARS

### 4.1 Target Species

Dogs.

### 4.2 Indications for use, specifying the target species

Treatment of the following conditions caused by bacteria sensitive to doxycycline:

Rhinitis caused by *Bordetella bronchiseptica* and *Pasteurella* spp.;

Bronchopneumonia caused by *Bordetella* spp. and *Pasteurella* spp.;

Interstitial nephritis caused by *Leptospira* spp.

### 4.3 Contraindications

Do not use in cases of hypersensitivity to tetracyclines or to any of the excipients.

### 4.4 Special warnings for each target species

None.

### 4.5 Special precautions for use

Special precautions for use in animals

The product should be administered with caution to animals with dysphagia or

diseases accompanied with vomiting, since administration of doxycycline hyclate tablets has been associated with oesophageal erosion.

In order to reduce the likelihood of oesophageal irritation as well as other gastrointestinal side effects, the product should be administered together with food. Special care should be taken when administering the product to animals with liver disease, since increases in hepatic enzymes have been documented in some animals after doxycycline treatment.

The product should be administered with caution to young animals, since tetracyclines as a class may cause permanent discolouration of the teeth, when administered during tooth development. However, human literature indicates that doxycycline is less likely than other tetracyclines to cause these abnormalities, due to its reduced ability to chelate calcium.

Due to the likely variability (time, geographical) in the occurrence of resistance of bacteria for doxycycline, bacteriological sampling and susceptibility testing are recommended. Official, national and regional antimicrobial policies should be taken into account when the product is used. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to doxycycline and may decrease the effectiveness of treatment with other tetracyclines, due to the potential for cross-resistance.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Tetracyclines may cause hypersensitivity (allergy) reactions.

People with known hypersensitivity to tetracyclines should avoid contact with the veterinary medicinal product.

Wash hands after use.

If you develop symptoms following exposure such as skin rash, seek medical advice immediately and show the package leaflet to the physician.

Doxycycline may cause gastrointestinal disturbances after accidental ingestion, especially by children. To avoid accidental ingestion, particularly by a child, unused tablet parts should be returned to the open blister space and inserted back into the carton. In case of accidental ingestion, particularly by children, seek medical advice.

#### **4.6 Adverse reactions (frequency and seriousness)**

Gastrointestinal disorders such as vomiting, diarrhoea and oesophagitis have been reported as side effects following doxycycline therapy.

In very young animals discoloration of the teeth may occur by the formation of a tetracycline-calcium phosphate complex.

Hypersensitivity reactions, photosensitivity and in exceptional cases photodermatitis may occur after exposure to intense daylight.

Retardation of skeletal growth of young animals (reversible upon discontinuation of therapy) is known to occur with use of other tetracyclines and might occur following administration of doxycycline.

#### **4.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Tetracyclines as a class can retard foetal skeletal development (fully reversible) and cause discolouration of the deciduous teeth. However, evidence from human literature suggests that doxycycline is less likely to cause these abnormalities than other tetracyclines. Use only according to the benefit/risk assessment by the responsible veterinarian.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with bactericidal antibiotics such as penicillins and cephalosporins. Oral absorbents and substances containing multivalent cations such as antacids and iron salts should not be used from 3 hours before to 3 hours after the administration of doxycycline. The half-life of doxycycline is reduced by concurrent administration of antiepileptic drugs such as phenobarbital and phenytoin.

#### **4.9 Amounts to be administered and administration route**

Oral use.


The recommended dose for dogs is 10 mg doxycycline per kg bodyweight per day. The majority of routine cases are expected to respond after between 5 and 7 days of therapy. Therapy should continue for 2 to 3 days beyond the clinical cure for acute infections. In chronic or refractory cases, a longer course of therapy, up to 14 days, may be required. In dogs with interstitial nephritis due to leptospirosis, treatment for 14 days is recommended. To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing. Tablets should be administered together with the food (see section 4.5).

The following table is intended as a guide to dispensing the product at the standard dose rate of 10 mg per kg bodyweight per day.

Body weight	Dose mg	Doxybactin 50 mg		Doxybactin 200 mg		Doxybactin 400 mg
0.75 kg – 1.25 kg	12.5			-		-
>1.25 kg – 2.5 kg	25			-		-
>2.5 kg – 3.75 kg	37.5			-		-
>3.75 kg – 5 kg	50			-		-
>5 kg – 6.25 kg	62.5	 		-		-
>6.25 kg – 7.5 kg	75	 		-		-
>7.5 kg – 10 kg	100	 		-		-
>10 kg – 12.5 kg	125	  		-		-
>12.5 kg – 15 kg	150	  				-
>15 kg – 20 kg	200	-				-
>20 kg – 25 kg	250		AND			-
>25 kg – 30 kg	300	-		 		-
>30 kg – 35 kg	350	-		 		-
>35 kg – 40 kg	400	-		-		
>40 kg – 45 kg	450		AND			
>45 kg – 50 kg	500	-			AND	
>50 kg – 60 kg	600	-			AND	
>60 kg – 70 kg	700	-		 	AND	
>70 kg – 80 kg	800	-		-		 

 = ¼ Tablet     = ½ Tablet     = ¾ Tablet     = 1 Tablet

Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the tablet on a flat surface, with its scored side facing up and the convex (rounded) side facing the surface.



2 equal parts: press down with your thumbs on both sides of the tablet.

4 equal parts: press down with your thumb in the middle of the tablet.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In cases of overdose no symptoms are to be expected other than those mentioned in section 4.6.

#### **4.11 Withdrawal period(s)**

Not applicable

### **5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antibacterial for systemic use, tetracyclines

ATCvet code: QJ01AA02

#### **5.1 Pharmacodynamic properties**

Doxycycline is a second-generation tetracycline. The product is mainly bacteriostatic; it inhibits bacterial protein synthesis by blocking the binding of transfer RNA at the messenger RNA-ribosome-complex. Doxycycline has a time-dependent concentration-enhanced effect with AUC/MIC being the main pharmacodynamic index.

Resistance is mainly mediated by efflux pumps or ribosomal protection proteins. Cross-resistance among tetracyclines is common but depends on resistance mechanisms: i.e. mutation in efflux pumps that renders resistance to tetracycline may still be sensitive to doxycycline. However, induction of the ribosomal protection proteins confers cross-resistance to doxycycline.

Bacterial species/group and origin	MIC <sub>90</sub>	Resistant (%)	Cut-off used
<b><i>Pasteurella</i> spp.</b>			
<i>P. multocida</i> (DE 2010)	0.5 µg/ml		
<i>P. multocida</i> (FR, 2013)		15%	8 µg/ml <sup>#</sup>
<b><i>Bordetella bronchiseptica</i></b>			
<i>B. bronchiseptica</i> (DE 2010-2011)	1 µg/ml		

# Based on the recommendations of the French CA-SFM (Comité de l'Antibiogramme de la Société Française de Microbiologie)

## 5.2 Pharmacokinetic properties

After oral administration doxycycline is mainly absorbed from the duodenum and jejunum. Following oral administration, the bioavailability is > 50%.

Doxycycline is widely distributed throughout the body and can accumulate intracellularly in for example leukocytes. It is deposited in active bone tissue and teeth. Doxycycline is primarily eliminated through faeces by direct intestinal excretion and to a lesser extent by glomerular excretion and biliary secretion.

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Sodium starch glycolate (type A)  
 Silica, colloidal anhydrous  
 Cellulose, microcrystalline  
 Yeast (dried)  
 Chicken flavour  
 Magnesium stearate

### 6.2 Incompatibilities

Not applicable

### 6.3 Shelf-life

Shelf life of the veterinary medicinal product as packaged for sale: 30 months  
 Shelf life of divided tablets: 3 days.

### 6.4 Special precautions for storage

Store below 30°C.

## **6.5 Nature and composition of immediate packaging**

Aluminium - PVC/PE/PVDC blister

Cardboard box of 1, 2 or 3 blisters of 10 tablets.

Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets.

Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7 MARKETING AUTHORISATION HOLDER**

Le Vet Beheer B.V.  
Wilgenweg 7  
3421 TV Oudewater  
Netherlands

## **8 MARKETING AUTHORISATION NUMBER(S)**

VPA10475/031/004

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 8<sup>th</sup> September 2017

## **10 DATE OF REVISION OF THE TEXT**